Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins Scientific SEERFSF -0.37%78 EV-to-EBITDA is 9.35 as of Jul. 25, 2026, which is 32% below its 10-year median of 13.68. GuruFocus rates ERFSF with a GF Score™ of 78/100 and a GF Value™ of $73.37 (Fairly Valued). The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks better than 66.67% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eurofins Scientific SE's enterprise value is $17,474 Mil.
Eurofins Scientific SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1,868 Mil. Therefore, Eurofins Scientific SE's EV-to-EBITDA for today is 9.35.
The historical rank and industry rank for Eurofins Scientific SE's EV-to-EBITDA or its related term are showing as below:
ERFSF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.07 Med: 13.68 Max: 25.17
Current: 9.55
During the past 13 years, the highest EV-to-EBITDA of Eurofins Scientific SE was 25.17. The lowest was 8.07. And the median was 13.68.
ERFSF's EV-to-EBITDA is ranked better than 66.67% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.61
vs ERFSF: 9.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Eurofins Scientific SE (OTCPK:ERFSF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eurofins Scientific SE's PE Ratio (TTM) for today is calculated as:
Eurofins Scientific SE's share price for today is $73.746.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eurofins Scientific SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $3.341.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's EV-to-EBITDA falls into.
Eurofins Scientific SE's current Enterprise Value is $17,474 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eurofins Scientific SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1,868 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a EV-to-EBITDA of 9.35 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eurofins Scientific SE. This is 32% below median its historical median of 13.68. Over the past decade, Eurofins Scientific SE's EV-to-EBITDA has ranged from 8.07 to 25.17. According to the industry distribution chart, Eurofins Scientific SE ranks #39 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 33.3%.
Is Eurofins Scientific SE's EV-to-EBITDA too high?
Eurofins Scientific SE's current EV-to-EBITDA of 9.35 is 32% below median its 10-year median of 13.68. Over the past 10 years, this metric has ranged from a low of 8.07 to a high of 25.17. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.61. Eurofins Scientific SE's value of 9.35 is 36% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #39 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #39 out of 117 companies for EV-to-EBITDA. This puts Eurofins Scientific SE in the upper half of its industry. The industry median EV-to-EBITDA is 14.61. Eurofins Scientific SE's value of 9.35 is 36% below this benchmark. Historically, Eurofins Scientific SE's own EV-to-EBITDA has ranged from 8.07 to 25.17 over the past decade. While the company's 10-year median is 13.68 vs. the industry median of 14.61, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.61, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current EV-to-EBITDA of 9.35 is 36% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eurofins Scientific SE. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current EV-to-EBITDA is 9.35, which is 32% below median its own 10-year median of 13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $73.37, compared to a current price of $73.75 — trading 0.5% above its estimated fair value. The current EV-to-EBITDA is 9.35, which is 32% below median its 10-year median of 13.68 and 36% below the Medical Diagnostics & Research industry median of 14.61. Eurofins Scientific SE's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current EV-to-EBITDA is 9.35 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $73.75 is trading 0.5% above its estimated GF Value™ of $73.37.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
EV-to-EBITDA: 9.35 (32% below median its 10-year median of 13.68)
GF Value™: $73.37 vs. price of $73.75 (0.5% above fair value)
Industry Position: 36% below the Medical Diagnostics & Research median (#39 of 117)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
78GF Score
Get the complete analysis for ERFSF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
